GlassScriptPhysician profile
Navya Nair
NPI 1952692048
$1,409.72
in general payments reported to CMS, 2019-2025
14 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $112 · 2021: $88.17 · 2022: $19.14 · 2023: $122 · 2024: $247 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.17 | 2024-2025 | |
| Eisai INC. | $173.96 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $172.56 | 2019-2020 | |
| Clovis Oncology, INC. | $130.51 | 2019 | |
| Prescient Surgical | $124.89 | 2019 | |
| Tesaro, INC. | $121.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $118.36 | 2019 | |
| Biom'Up France Sas | $48.05 | 2021 | |
| Baxter Healthcare | $40.12 | 2021 | |
| Daiichi Sankyo INC. | $27.57 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $21.03 | 2024 | Zejula, Jemperli |
| Pacira Pharmaceuticals Incorporated | $19.14 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.65 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navya Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.